康美药业(600518.SH)发布前三季度业绩，归母净利润1308万元，同比增长160.84%

Core Insights - Kangmei Pharmaceutical (600518.SH) reported its Q3 2025 results, showing a revenue of 3.96 billion yuan for the first three quarters, representing a year-on-year growth of 2.22% [1] - The company's net profit attributable to shareholders reached 13.08 million yuan, marking a significant year-on-year increase of 160.84% [1] - However, the company reported a non-recurring net profit loss of 37.94 million yuan, with basic earnings per share at 0.001 yuan [1]